Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Torres, E. Bouza, R. Pallarés, L. Molinos, M. Salavert, P. Llinares, J. L. De la Cruz, I. Alfageme, O. Rajas, A. Fenoll, J. Liñares, C. Méndez (Barcelona, Madrid, Oviedo, Valencia, A Coruña, Málaga, Sevilla, Spain). Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013). Eur Respir J 2014; 44: Suppl. 58, 1050

Member's Comments

No comment yet.

Related content which might interest you: Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Underlying clinical conditions and invasive pneumococcal disease (IPD) in adults in Spain (ODIN study, 2010-2012) Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden Source: Eur Respir J 2016; 47: 1208-1218 Year: 2016 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Evolution of serotype coverages of 23- and 7-valent pneumococcal vacciness for S. pneumonia isolates from Spanish middle age and older adults with pneumonia, 2002-2007 Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia Source: Eur Respir J 2004; 24: Suppl. 48, 363s Year: 2004 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Compliance with the pneumococcal and influenza vaccination recommendations in patients with COPD in Catalonia (Spain) Source: Eur Respir J 2005; 26: Suppl. 49, 594s Year: 2005 A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021 Year: 2022 Evolutionary trend of invasive pneumococcal disease according to serotypes Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Pneumococcal carriage and serotypes distribution in patients with acute otitis media in Switzerland, 2004-2014 Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016 Influence of comorbidities in the clinical presentation of invasive pneumococcal disease (IPD) in adults in Spain, 2010-2013. The ODIN study Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Increasing prevalence of complicated pneumonia and pneumococcal related hemolytic uremic syndrome despite territory-wide program of pneumococcal conjugated vaccination (PCV-7) program in children Source: International Congress 2014 – Paediatric epidemiology: wheeze, asthma and other respiratory diseases Year: 2014